Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,530
datasets available to search
ShareScore release 0.9.0
Dataset results
1,530 results for “treatment response”
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Dis
ClinicalTrials.gov study NCT00266409. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
ClinicalTrials.gov study NCT00623766. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
ClinicalTrials.gov study NCT03326193. IPD Sharing: NO. Countries: 1. Publications: 1.
Effect of Serum Vitamin D on MARPE Treatment Response
ClinicalTrials.gov study NCT06943443. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
ClinicalTrials.gov study NCT02305849. IPD Sharing: YES. Countries: 1. Publications: 5.
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
ClinicalTrials.gov study NCT01425749. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
ClinicalTrials.gov study NCT00502840. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: The 15-year post-treatment response of a mixed-conifer understory plant community to thinning and burning treatments
Open the record for dataset details and reuse information.
Data from: Serum metabolomics predicts treatment response in myasthenia gravis
Open the record for dataset details and reuse information.
Osmia lignaria larval development response to heatwave treatments
Open the record for dataset details and reuse information.
N2O and CO2 fluxes and related environmental conditions in response to manure and synthetic fertilization treatments, with and without a urease inhibitor
Open the record for dataset details and reuse information.
Do tradeoffs govern plant species responses to different global change treatments?
Open the record for dataset details and reuse information.
Non-target woody plant responses to broadcast herbicide treatment for mesquite and pricklypear control
Open the record for dataset details and reuse information.
Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data
Open the record for dataset details and reuse information.
Data from: Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: comparison with conventional DCE-MRI
<p><strong>Purpose:</strong> To investigate the validity of contrast kinetic parameter estimates from Active Contrast Encoding (ACE)-MRI against those from conventional Dynamic Contrast-Enhanced (DCE)-MRI for evaluation of tumor treatment response in mouse tumor models.</p> <p><strong>Methods:</strong> The ACE-MRI method that incorporates measurement of <em>T<sub>1</sub></em> and <em>B<sub>1</sub></em> into the enhancement curve washout region, was implemented on a 7T MRI scanner to measure tracer kinetic model parameters of 4T1 and GL261 tumors with treatment using bevacizumab and 5FU. A portion of the same ACE-MRI data was used for conventional DCE-MRI data analysis with a separately measured pre-contrast <em>T<sub>1</sub></em> map. Tracer kinetic model parameters, such as <em>K<sup>trans</sup></em> (permeability area surface product) and <em>v<sub>e</sub></em> (extracellular space volume fraction), estimated from ACE-MRI were compared with those from DCE-MRI, in terms of correlation and Bland-Altman analyses. </p> <p><strong>Results:</strong> A three-fold increase of the median <em>K<sup>trans</sup></em> by treatment was observed in the flank 4T1 tumors by both ACE-MRI and DCE-MRI. In contrast, the brain tumors did not show a significant change by the treatment in either ACE-MRI or DCE-MRI. <em>K<sup>trans</sup></em> and <em>v<sub>e</sub></em> values of the tumors from ACE-MRI were strongly correlated with those from DCE-MRI methods with correlation coefficients of 0.92 and 0.78, respectively, for the median values of 17 tumors. The Bland-Altman plot analysis showed a mean difference of -0.01 /min for <em>K<sup>trans</sup></em> with the 95% limits of agreement of -0.12 /min to 0.09 /min, and -0.05 with -0.37 to 0.26 for <em>v<sub>e</sub></em>.</p> <p><strong>Conclusion:</strong> The tracer kinetic model parameters estimated from ACE-MRI and their changes by treatment closely matched those of DCE-MRI, which suggests that ACE-MRI can be used in place of conventional DCE-MRI for tumor progression monitoring and treatment response evaluation with a reduced scan time. <br> </p>
Short-term responses to high-dose inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease having a fractional nitric oxide concentration over 35 parts per billion: a single-center pre-post study
<p>Background: There is currently no strategy to identify chronic obstructive pulmonary disease (COPD) patients whose pulmonary function could benefit from inhaled corticosteroids. This study investigates whether a 28-day regime of inhaled corticosteroids improves pulmonary function test results among chronic obstructive pulmonary disease patients having a fractional exhaled nitric oxide concentration > 35 parts per billion.<br> Methods: This was a single-center one-arm pre–post trial. Chronic obstructive pulmonary disease patients with a fractional exhaled nitric oxide concentration > 35 parts per billion treated at our institution from September 2018 to August 2019 were included. Each patient was administered budesonide (200 μg, 8 puffs daily) for 28 days. The primary outcome measure was the difference between the values of forced expiratory volume in 1 s (FEV1) at baseline and 28 days after inhaled corticosteroid initiation. Secondary outcomes included differences of Chronic Obstructive Pulmonary Disease Assessment Test scores, %FEV1, and that between the percent forced vital capacity at baseline and 28 days after inhaled corticosteroid initiation.<br> Results: Twenty patients were included; all patients completed the 28-day inhaled corticosteroid regime. The mean difference in FEV1 between day 1 and 28 days after inhaled corticosteroid initiation was 340 mL (95% confidence interval: −100 to 770 mL; p = 0.122). The mean differences in secondary outcomes were: % forced vital capacity , −0.16% (95% confidence interval: −2.84 to 2.53%; p = 0.905); %FEV1, 1.63% (95% confidence interval: −4.56 to 7.81%; p = 0.589); Chronic Obstructive Pulmonary Disease Assessment Test score, −2.50 (95% confidence interval: −5.72 to 0.72; p = 0.121).<br> Conclusion: The 28-day course of inhaled corticosteroids showed no significant difference in FEV1 for chronic obstructive pulmonary disease patients having fractional exhaled nitric oxide concentration > 35 parts per billion.<br> </p>
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Objective: The aim of this study was to prospectively evaluate the feasibility of monitoring treatment response to chemotherapy in patients with non-small cell lung carcinoma using functional diffusion maps (fDMs). Materials and Methods: This study was approved by the Cantonal Research Ethics Committee and informed written consent was obtained from all patients. Nine patients (mean age = 66 years; range = 53–76 years, 5 females, 4 males) with overall 13 lesions were included. Imaging was performed within two weeks before initiation of chemotherapy and at one, two, and six weeks after initiation of chemotherapy. Imaging included a respiratory-triggered diffusion-weighted sequence including three b-factors (100, 600, and 800 s/mm2). Treatment response was defined by change in tumor diameter on computed tomography (CT) after two cycles of chemotherapy. Changes in the apparent diffusion coefficient (ADC) on a per-lesion basis and the percentages of voxel with significantly increased or decreased ADCs on fDMs were analyzed using repeated measures analysis of variance (ANOVA). Changes in tumor size were used as covariate to examine the ability of ADCs and fDM parameters to predict treatment response. Results: Repeated measures ANOVA revealed that the percentage of voxels with increased ADCs on fDMs (p = 0.002) as well as the mean ADC increase (p = 0.011) were significantly higher in good responders with a large reduction in tumor size on CT. Conclusion: Our results indicate that the percentage of voxels with significantly increased ADCs on fDMs seems to be a promising biomarker for early prediction of treatment response in patients with non-small cell lung carcinoma. Contrary to averaged values, this approach allows the spatial heterogeneity of treatment response to be resolved.
Underlying data for The Impact of ABCB1 (rs1045642 and rs117068084) Gene Polymorphisms on Response to Imatinib Treatment in A Sample of Iraqi Chronic Myeloid Leukemia-Chronic Phase Patients
<p>Underlying data for The Impact of ABCB1 (rs1045642 and rs117068084) Gene Polymorphisms on Response to Imatinib Treatment in A Sample of Iraqi Chronic Myeloid Leukemia-Chronic Phase Patients </p>
Data from: Annual ryegrass (Lolium multiflorum Lam.) growth response to nitrogen in a sandy soil amended with acidified manure and municipal sludge after "Quick Wash" treatment
<p>The Quick Wash (QW) treatment extracts phosphorus (P) from manure and municipal sludge (MS), producing an organic acidified by-product with adequate nitrogen (N):P ratio to meet crop N requirements. Yet, data on crop response to N using QW by-products are lacking. We evaluated the response of annual ryegrass (<span class="html-italic">Lolium multiflorum</span> Lam.) and potential N leaching in sandy soil to N applications using raw wastes, their corresponding QW by-products, and ammonium sulfate (AMS) fertilizer. Treatments included a control (no amendment added), raw and acid-washed chicken litter, dairy and swine manure, MS, and AMS at 100, 200, and 400 kg N ha<sup>−1</sup>.</p>
Blood memory CD8 T cell phenotypes in lung cancer patients predict immune checkpoint treatment responses
<p>Rscript for figure generation and data analysis:</p> <p>GenerateFigures.R</p> <p> </p> <p>Seurat objects containing processed data after quality control:</p> <p><a href="../api/records/10867209/draft/files/NCCS_For_Zenodo.RDS/content" target="_blank" rel="noopener noreferrer">NCCS_For_Zenodo.RDS</a> - NCCS discovery cohort.</p> <p><a href="../api/records/10867209/draft/files/Pavia_For_Zenodo.RDS/content" target="_blank" rel="noopener noreferrer">Pavia_For_Zenodo.RDS</a> - Pavia validation cohort.</p> <p> </p> <p>RDS files containing DEGs or differentially abundant surface markers:</p> <p>TestResults2Groups.rds - Cell type specific LTR vs Non Responder DEG </p> <p>TestResults2GroupsADT.rds - Cell type specific LTR vs Non Responder differential surface markers</p> <p>TestResults2GroupsLungOnly.rds - Cell type specific LTR vs Non Responder DEG on lung samples only</p> <p>TestResults2GroupsLungOnlyADT.rds - Cell type specific LTR vs Non Responder differential surface markers on lung samples only</p> <p>TestResults3Groups.rds - Cell type specific LTR vs R vs Non Responder differential DEG</p> <p>TestResults3GroupsGeneralADT.rds - Across cell type LTR vs R vs Non Responder differential surface markers</p> <p>TestResults2GroupsGeneralRNA.rds - Across cell type LTR vs Non Responder DEG </p> <p>TestResults2GroupsGeneralADT.rds - Across cell type LTR vs Non Responder differential surface markers</p> <p>TestResults2GroupsLungOnlyGeneralRNA.rds - Across cell type LTR vs Non Responder DEG on lung samples only</p> <p>TestResults2GroupsLungOnlyGeneralADT.rds - Across cell type LTR vs Non Responder differential surface markers on lung samples only</p> <p>TestResults3GroupsGeneralRNA.rds - Across cell type LTR vs R vs Non Responder differential DEG</p> <p>TestResults3GroupsGeneralADT.rds - Across cell type LTR vs R vs Non Responder differential surface markers</p> <p> </p> <p>Logistic regression models trained on the NCCS discovery cohort:</p> <p>PerCellPredictions <CellType> * - Celltype specific models predicting either LTR, R or control group trained on all NCCS samples</p> <p>PerCellPredictions_2Groups_LungOnly <CellType> * - Celltype specific models predicting either LTR or NonResponder group, trained on lung samples only.</p> <p>PerCellPredictions_2Groups_<CellType> * - Celltype specific models predicting either LTR or NonResponder trained on all NCCS samples</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.